Impact of the additional/booster dose of COVID-19 vaccine against severe disease during the epidemic phase characterized by the predominance of the Omicron variant in Italy, November 2021 - March 2022
Branda, F.
Show abstract
Vaccine effectiveness (VE) against emerging SARS-CoV-2 variants is a growing issue. The aim of this work is to evaluate the impact of the COVID-19 additional/booster dose against COVID-19-related symptoms, hospitalization, and death using surveillance data (December 2021-May 2022) from the Italian National Institute of Health (ISS). As of 18 May 2022, for people fully vaccinated with three doses, VE was 87.8% (95% confidence interval (CI): 87.6-88.0), whereas VE decreased from 71.5% (95% CI: 71.0-72.0) in those vaccinated > 120 days to 69.6% (95% CI: 68.3-70.8) within 91-120 days. Results support the importance of receiving a third dose of mRNA COVID-19 vaccine.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Impact of CoronaVac on Covid-19 outcomes of elderly adults in a large and socially unequal Brazilian city: A target trial emulation study 97%
- Effectiveness of second booster compared to first booster and protection conferred by previous SARS CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France 97%
- Antibody Response after Second-dose of ChAdOx1-nCOV (Covishield™ ® ) and BBV-152 (Covaxin™ ® ) among Health Care Workers in India: Final Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study 96%
Similar papers in this journal
- Safety and efficacy of two immunization schedules with an inactivated SARS-CoV-2 vaccine in adults. A randomized non-inferiority clinical trial 96%
- Long-Term Immunogenicity Study of an Aluminum Phosphate-Adjuvanted Inactivated Enterovirus A71 Vaccine in Children: An Extension to a Phase 2 Study 96%
- Safety and immunogenicity of the BBIBP-CorV vaccine in adolescents aged 12-17 years in Thai population, prospective cohort study 95%
Similar papers in this journal
- COVID-19 vaccine effectiveness against laboratory confirmed symptomatic SARS-CoV-2 infection, COVID-19 related hospitalizations and deaths, among individuals aged 65 years or more in Portugal: a cohort study based on data-linkage of national registries February-September 2021 97%
- Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalization among Finnish elderly and chronically ill – An interim analysis of a nationwide cohort study 97%
- Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru 96%
Similar papers in this journal
- mRNA vaccines effectiveness against COVID-19 hospitalizations and deaths in older adults: a cohort study based on data-linkage of national health registries in Portugal 96%
- Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection in the Netherlands, September to December 2022 95%
- Impact of age, gender, ethnicity and prior disease status on immunogenicity following administration of a single dose of the BNT162b2 mRNA Covid-19 Vaccine: real-world evidence from Israeli healthcare workers, December-January 2020 93%
Similar papers in this journal
- Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination 96%
- Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS) 95%
- Hospitalized patients with severe COVID-19 during the Omicron wave in Israel - benefits of a fourth vaccine dose 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.